Since glaucoma is the second leading cause of blindness in the world, and the number of patients is increasing in the aging society [38], other low-molecular-weight compounds that have neuroprotective effects may be useful in combination with DOCK3 activator. The gene discussed is DOCK3; the disease is blindness (disorder).